Citi Appointed Successor Depositary Bank for AstraZeneca?s ADRProgramme

09/02/2015 - 10:10

Citi’s Issuer Services business, acting through Citibank N.A., has been appointed by AstraZeneca PLC (“AstraZeneca”), a leading global biopharmaceutical company, as the successor depositary bank for their New York Stock Exchange (NYSE) listed American Depositary Receipt (ADR) programme. AstraZeneca’s American Depositary Shares trade on the NYSE under the symbol “AZN”. AstraZeneca’s ordinary shares are also listed and trade on the London and Stockholm Stock Exchanges under the symbol “AZN”.

“It’s a privilege to be appointed by AstraZeneca as successor depositary bank for their ADR programme,” Dirk Jones, Global Head of Issuer Services said, “With Citi’s excellent investor relations expertise and unmatched global equity distribution network, we’re confident we can provide outstanding investor access and awareness to AstraZeneca’s ADR programme”.

For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.

NOTES TO EDITORS

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.